Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Year Ended 31st March, 2026
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI (LODR) Regulations, 2015, comprising approval of audited financial results, dividend recommendation, and cost auditor appointment.
Audit Opinion:
The Statutory Auditors, M/s. Krishaan & Co., Chartered Accountants, issued an unmodified (clean) audit opinion on both the Standalone and Consolidated Annual Financial Results.
Auditor’s Comment:
The auditors confirmed the financial results give a true and fair view and are prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI Listing Regulations. No qualifications or modifications were reported.
Key Financial Highlights [Amount in INR Lakhs]:
Standalone Results:
Revenue from Operations:
- Q4 FY26: ₹7,653.05 (vs. Q4 FY25: ₹7,170.16; +6.7% YoY)
- Full Year FY26: ₹34,223.55 (vs. FY25: ₹40,551.16; -15.6% YoY)
Total Income:
- Q4 FY26: ₹8,019.75
- Full Year FY26: ₹35,159.71
Net Profit/(Loss):
- Q4 FY26 Net Profit: ₹196.56 (vs. Q4 FY25 Net Loss: ₹(774.48))
- Full Year FY26 Net Loss: ₹(1,418.55) (vs. FY25 Net Profit: ₹2,392.15)
EPS (of ₹1 each):
- Basic & Diluted Q4 FY26: ₹0.21
- Basic & Diluted Full Year FY26: ₹(1.54)
Other Equity (Excluding Revaluation Reserve):
- As of 31st March 2026: ₹25,916.47
Cash and Cash Equivalents:
- As of 31st March 2026: ₹444.81
Debt:
- Non-current Borrowings: ₹2,186.23
- Current Borrowings: ₹7,822.89
- Total Borrowings: ₹10,009.12
Consolidated Results:
Revenue from Operations:
- Q4 FY26: ₹7,653.05
- Full Year FY26: ₹34,223.55
Total Income:
- Q4 FY26: ₹8,019.75
- Full Year FY26: ₹35,159.71
Net Profit/(Loss) Attributable to Equity Holders of Parent:
- Q4 FY26 Net Profit: ₹888.55
- Full Year FY26 Net Profit: ₹114.39
EPS (of ₹1 each):
- Basic & Diluted Q4 FY26: ₹0.96
- Basic & Diluted Full Year FY26: ₹0.12
Other Equity (Excluding Revaluation Reserve):
- As of 31st March 2026: ₹35,680.28
Cash and Cash Equivalents:
- As of 31st March 2026: ₹453.81
Debt:
- Non-current Borrowings: ₹2,186.23
- Current Borrowings: ₹7,822.89
- Total Borrowings: ₹10,009.12
Segment-wise Performance:
The company operates in a single business segment, i.e., Pharmaceuticals, and hence does not have any reportable segments as per Ind AS 108.
Corporate Actions:
Dividend: The Board recommended a final dividend of ₹0.50 (i.e., 50%) per equity share of face value ₹1/- each for FY26, aggregating to ₹4,60,50,060. This is subject to approval by shareholders at the forthcoming Annual General Meeting.
Other Significant Information:
Exceptional Items:
- An exceptional item of ₹86.53 lacs (net) was recorded in Q3 FY25 and FY26 due to the incremental impact of the newly notified Labour Codes (Code on Wages 2019, Industrial Relations Code 2020, Code on Social Security 2020, and Occupational Safety Code 2020). This was classified as exceptional due to its regulatory-driven and non-recurring nature.
- An exceptional item of ₹129.39 lacs was recorded in FY26 for the write-off related to the dissolved UK subsidiary, Carpo Medicals Limited.
Entities in Consolidation:
The consolidated results include:
- Subsidiaries: Themis Chemicals Private Limited, Artemis Biotech Limited, Dr. Themis Private Limited.
- Associates: Gujarat Themis Biosyn Limited, Long Island Nutritionals Private Limited.
- Associate (Joint Venture): Richter Themis Medicare (India) Private Limited.
Share of Profit from Associates/JV: The share of profit from associates and joint venture for FY26 was ₹1,404.84 lakhs, significantly contributing to the consolidated net profit.